|
Healthcare-associated infections (HAIs) are a major cause of morbidity and mortality around the world. An estimated 6 million healthcare-associated infections occur each year across the U.S., Europe and Japan alone. In the U.S. up to 90,000 patients die as a result of healthcare-associated infections each year, making healthcare-associated infections the fourth leading cause of death. Beyond the human toll, there is an enormous financial burden to healthcare systems worldwide. BD is committed to applying its expertise, resources and technologies toward the prevention of healthcare-associated infections worldwide. If you are a member of the media and have questions about these materials, please contact Alyssa Zeff, Director, WW Public Relations at alyssa_zeff@bd.com.
Backgrounders
News Releases
Events
Multimedia Resources
Additional Resources
Backgrounders
 Healthcare-Associated Infections At A Glance 
Methicillin-resistant Staphylococcus aureus At A Glance
Clostridium difficile Infection (CDI) Backgrounder
Active Surveillance At A Glance
BD GeneOhm™ MRSA Assay At A Glance
BD GeneOhm™ Cdiff Assay Backgrounder
Benefits of Rapid Testing
Key Research Papers Relevant to the BD GeneOhm™ MRSA Assay
Emergence of MRSA Timeline
HAI Terminology Guide
Return to top
News Releases
- BD Diagnostics and Biodiversity Collaborate to Develop Portfolio of Assays on the BD MAX™ System (August 18, 2011)
- BD and Lab21 Collaborate to Develop Aspergillus Assay for New BD MAX™ Molecular Testing System (August 3, 2011)
- BD Diagnostics Hires Leading Infectious Disease Diagnostics Expert to Strengthen New Product Pipeline (July 6, 2011)
- BD Launches BD MAX™ System in U.S. to Empower Laboratories and Clinicians to Respond to Emerging Diseases (May 19, 2011)
- BD and Diagenode Collaborate to Expand Infectious Disease Menu on the BD MAX™ System (May 9, 2011)
- BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians (May 6, 2011)
- World Health Day Emphasis on Antimicrobial Resistance Brings Much-Needed Awareness to Alarming Issue (April 7, 2011)
- New CDC Guidelines Recognize Value of Split Septum IV Access Technology to Reduce Intravascular Catheter-Related Bloodstream Infections (April 4, 2011)
- BD Taps Leading Voice in Infection Prevention Community to Advance Efforts to Reduce Healthcare-Associated Infections (November 16, 2010)
- BD Diagnostics and Lonza Collaborate to Commercialize the Lonza microCompass™ Molecular Assays on the BD MAX™ System (October 25, 2010)
- BD Diagnostics and Bruker Collaborate to Improve Microbial Identification and Antimicrobial Susceptibility Testing (September 29, 2010)
- BD Receives CLIA "Moderate Complexity" Status for the BD MAX™ GBS Assay (August 3, 2010)
- BD Announces First FDA-Cleared Assay on the BD MAX™ System to Detect Group B Streptococcus (June 2, 2010)
- BD Diagnostics Launches the BD Protect™ Infection Surveillance and Prevention Software Portfolio (March 18, 2010)
- New Product Announcement (December 24, 2009)
- BD Announces Agreement to Acquire HandyLab, Inc. (October 23, 2009)
- BD Adds Surveillance Capability to Infectious Disease Portfolio:
Software Monitors and Reports Emerging Infection Issues (August 6, 2009)
- APIC Announces Launch of Online Education Center for Instant Access to Comprehensive Infection Prevention
(August 5, 2009)
- BD and HandyLab Announce Exclusive Collaboration to Commercialize Molecular Assays (May 18, 2009)
- BD Announces FDA 510(k) Clearance of Novel Molecular Assay to Diagnose Clostridium difficile Infections (January 12, 2009)
- BD Selected to Participate in Premier QUEST Nationwide Hospital Collaborative to Reduce Healthcare-Associated Infections (December 3, 2008)
- BD Announces Health Canada Licensing of Novel Molecular Assay for Detection of Clostridium difficile Toxin B Gene (November 20, 2008)
- BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections (July 7, 2008)
- BD Celebrates Opening of New Manufacturing Center in Québec (June 10, 2008)
- New BD BACTEC™ FX Blood Culture Instrument with the BD EpiCenter™ Operating System can Facilitate Fast and Effective Clinical Decisions for Patients with Bacterial Infections (June 2, 2008)
- BD Announces CE Marking of the BD GeneOhm™ VanR Molecular Test for the Rapid Detection of Vancomycin Resistance (May 1, 2008)
- Preliminary Data from Pitt County Memorial Hospital Study Show Benefit of Active Surveillance on Reducing MRSA VAP Rates in Surgical ICU (April 7, 2008)
- GeneOhm™ MRSA Assay Part of Largest U.S. Study Using Universal Active Surveillance to Significantly Reduce MRSA Infection Rates (March 17, 2008)
- BD Announces FDA 510(k) Clearance of Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures (January 2, 2008)
- BD Announces CE Marking of Rapid Molecular Test to Identify Superbug from Nasal and Wound Specimens (December 20, 2007)
- UCLH Study Demonstrates Rapid Patient Screening Could Cut MRSA Rates By Almost 40 percent (December 18, 2007)
- Screening for Nasal Carriage of MRSA: Reduction of Turnaround Time and Workload by the use of BD BBL™ CHROMagar™ MRSA (October 4, 2007)
- BD GeneOhm's Flagship Client, Evanston Northwestern Healthcare, Receives Prestigious Patient Safety Award from the NQF and the Joint Commission for its MRSA Prevention Program (September 12, 2007)
- BD Demonstrates Microbiology Automation Designed to Improve Laboratory Efficiency of Microbial Identification and Susceptibility Testing (May 22, 2007)
- BD Receives CE Mark Approval for Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures (May 21, 2007)
- BD Announces FDA 510(k) Submission of Two Hour Test to Identify Superbug in Patients with Positive Blood Cultures (April 25, 2007)
- BD Helping APIC to Expand its Mission in HAIs Prevention at the APIC Futures Summit (January 27, 2007)
- "Grand Rounds" Address Impact of Antibiotic-Resistant Superbug on Healthcare Facilities (November 16, 2006)
- Evanston Northwestern Healthcare Study Reveals Who is Most at Risk for Carrying MRSA (November 6, 2006)
- Evanston Northwestern Healthcare Study Shows Benefit of Universal Surveillance (November 5, 2006)
- BD Completes Acquisition of GeneOhm Sciences, Inc. (February 14, 2006)
Return to top
Events
 Upcoming Events
Return to top
Multimedia Resources
BD on TV (Videos)
- CEO Ed Ludwig Discusses Healthcare-associated Infections on CNBC (October 22, 2007)
Return to top
Additional Resources
Visit our Healthcare-Associated Infections Site
Permission Request Form (to use BD logo or for reprint and distribution of BD materials)
Return to top
|
